Clinical Trials

Esophageal Neoplasms

NCT06610734 2026-02-09

SKY

202 enrolled

Phase EARLY_PHASE1 Active not recruiting

Small Cell Lung Cancer Extensive Stage

NCT05358938 2026-02-06

Exercise to Boost Response to Checkpoint Blockade Immunotherapy

22 enrolled

Dermatologic

Melanoma, Motor Activity, Skin Neoplasms, Carcinoma, Merkel Cell

NCT07385989 2026-02-04

Golidocitinib Combined With P-GemOx Plus PD-1 Inhibitor Versus P-GemOx Plus PD-1 Inhibitor in First-Line Newly Diagnosed Advanced or Non-Nasal Extranodal NK/T-Cell Lymphoma

40 enrolled

Lymphoid

Lymphoma, Extranodal NK-T-Cell

NCT06627712 2026-01-30

SBRT Combined With PD-1 Inhibitor and Chemotherapy in Early-stage TNBC

Phase 3 Recruiting

318 enrolled

Breast

Triple Negative Breast Neoplasms

NCT05166239 2026-01-23

HAIC Combine With Lenvatinib and PD-1 Inhibitors for Advanced HCC With PVTT

Phase 2 Completed

66 enrolled

Phase 1 Not yet recruiting

Carcinoma, Hepatocellular

NCT07363369 2026-01-23

Exploratory Clinical Study of FAP mRNA Vaccine in Patients With Advanced Malignant Solid Tumors

10 enrolled

Advanced Malignant Solid Tumors

NCT07364305 2026-01-23

Lalo

Phase 2 Active not recruiting

50 enrolled

ICC

NCT04995003 2026-01-22

HER2 Chimeric Antigen Receptor (CAR) T Cells in Combination With Checkpoint Blockade in Patients With Advanced Sarcoma

Phase 1 Recruiting

25 enrolled

Sarcoma

Rhabdomyosarcoma, Sarcoma, Sarcoma, Ewing, Osteosarcoma, Sarcoma, Synovial

NCT07339488 2026-01-14

ILDR-03

43 enrolled

Esophageal Squamous Cell Carcinoma

NCT07327411 2026-01-08

Cetuximab β Combined With PRaG Regimen in the Treatment of EGFR-positive Advanced Refractory Solid Tumors

40 enrolled

Advanced Refractory Solid Tumors

NCT07317778 2026-01-05

Chemotherapy With or Without Adebrelimab and T-DXh as Neoadjuvant Therapy for HR+/HER2 Low Early Stage Breast Cancer

249 enrolled

Breast

Breast Cancer Early Stage Breast Cancer (Stage 1-3)

NCT07230639 2025-12-26

MODIFI-CC

52 enrolled

Neoadjuvant Therapies

NCT07279077 2025-12-26

MODIFI-L

38 enrolled

Colonic Neoplasms

NCT07282184 2025-12-18

Multimodal Deep Learning for Postoperative Liver Cancer Risk Stratification and Intervention

Phase 1/2 Recruiting

144 enrolled

Phase 1/2 Active not recruiting

Carcinoma, Hepatocellular

NCT05013450 2025-12-17

Dupilumab_Metastatic NSCLC

33 enrolled

Carcinoma, Non-Small-Cell Lung

NCT06349837 2025-12-17

Safety and Tolerability of LDRT Plus Concurrent Partial SBRT and Tislelizumab in Patients With Bulky Tumors

Phase 1 Recruiting

24 enrolled

Solid Tumor

NCT07285395 2025-12-16

AT1019 Plus SBRT and PD-1 Inhibitor for Advanced Solid Tumors: An IIT Study

Phase 1 Recruiting

12 enrolled

Advanced Solid Tumors

NCT07282262 2025-12-15

An Exploratory Study on the Use of Ivosidenib for the Precise Treatment of Advanced Biliary Tract Malignancies With IDH1 Mutations in the Later Line of Therapy.

300 enrolled

Biliary Tract Neoplasms

NCT07271602 2025-12-09

A Phase 2 Randomized, Controlled Trial of QL1706 Plus Chemotherapy and Quad Shot for Driver Gene-negative Advanced Non-small Cell Lung Cancer.

104 enrolled

Carcinoma, Non-Small-Cell Lung

NCT05440916 2025-12-02

PRIMM

Phase 2 Completed

50 enrolled

Carcinoma, Non-Small-Cell Lung

NCT06248554 2025-12-02

Adjuvant PD-1 Inhibitor for Patients With Early-stage Hepatocellular Carcinoma Following Microwave Ablation

Phase NA Recruiting

200 enrolled

Carcinoma, Hepatocellular

NCT06154538 2025-11-28

Immune Checkpoint Inhibitors + Chemotherapy Versus Chemotherapy in the Neoadjuvant Treatment of Locally Advanced Colorectal Cancer

170 enrolled

Phase 3 Not yet recruiting

Locally Advanced Colorectal Carcinoma

NCT07238569 2025-11-20

Phase III Trial of EBV-DNA-Guided Adaptive Immunotherapy for Advanced Nasopharyngeal Carcinoma

516 enrolled

Head & Neck

Nasopharyngeal Cancinoma (NPC)

NCT06496373 2025-11-17

Clinical Study of mRNA Vaccine Combined With PD-1 Inhibitor as Adjuvant Therapy for Postoperative Pancreatic Cancer

Phase EARLY_PHASE1 Recruiting

20 enrolled

Pancreatic Neoplasms

NCT07230301 2025-11-17

Adebrelimab Infusion Plus Standard Care for Pancreatic Cancer With Pleural or Peritoneal Effusions

20 enrolled

Phase 2 Active not recruiting

Pancreatic Cancer Metastatic

NCT05241340 2025-10-24

RAD-VACCINE

33 enrolled

Genitourinary

Urinary Bladder Diseases, Urinary Bladder Neoplasms, Urologic Diseases, Urologic Neoplasms

NCT04954599 2025-10-07

Phase 1/2 Clinical Trial of CP-506 (HAP) in Monotherapy or With Carboplatin or ICI

Phase 1/2 Recruiting

126 enrolled

BreastGastrointestinalGenitourinaryGynecologicHead & Neck

Head and Neck Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Triple Negative Breast Neoplasms

NCT07070479 2025-09-18

Combination Therapy for PD-1 Resistant Recurrent or Metastatic Nasopharyngeal Carcinoma: A Bayesian Adaptive Phase II Trial

Phase 1/2 Not yet recruiting

208 enrolled

Head & Neck

Nasopharyngeal Carcinoma, Neoplasm Metastasis, Recurrence

NCT05806385 2025-09-09

LOGIC

36 enrolled

Breast

Triple Negative Breast Neoplasms

NCT07007182 2025-09-05

Conversion Therapy Plus Surgery and Radiotherapy for Retroperitoneal Nodal Metastases in Gastric Cancer

54 enrolled

Stomach Neoplasms

NCT07157306 2025-09-05

Gecacitinib Combined With Donafenib and PD-1 Inhibitor as Immune Rechallenge Therapy for Unresectable Hepatocellular Carcinoma

35 enrolled

Phase 4 Not yet recruiting

Carcinoma, Hepatocellular

NCT07149181 2025-08-29

Comparing the Efficacy and Safety of Chemotherapy Combined With or Without Immunotherapy as Postoperative Adjuvant Regimens in Patients With Resectable Gastric Cancer/Adenocarcinoma of the Esophagogastric Junction After Radical Surgery

1,000 enrolled

Phase 4 Not yet recruiting

Gastric / Gastroesophageal Junction Adenocarcinoma

NCT07132528 2025-08-20

Comparing the Efficacy and Safety of Chemotherapy Combined With or Without Immunotherapy as an Adjuvant Treatment After Radical Surgery for Patients With Resectable Adenocarcinoma of the Esophagogastric Junction of Gastric Cancer

1,000 enrolled